ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryo… Read more
Market Cap & Net Worth: ProKidney Corp. (PROK)
ProKidney Corp. (NASDAQ:PROK) has a market capitalization of $294.41 Million ($294.41 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15198 globally and #5993 in its home market, demonstrating a -16.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ProKidney Corp.'s stock price $2.08 by its total outstanding shares 141545448 (141.55 Million).
ProKidney Corp. Market Cap History: 2021 to 2026
ProKidney Corp.'s market capitalization history from 2021 to 2026. Data shows change from $1.40 Billion to $294.41 Million (-28.48% CAGR).
Index Memberships
ProKidney Corp. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.01% | #401 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1424 of 3165 |
Weight: ProKidney Corp.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ProKidney Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ProKidney Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3147.52x
ProKidney Corp.'s market cap is 3147.52 times its annual revenue
1740.90x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $239.21 Million | $76.00K | -$61.19 Million | 3147.52x | N/A |
Competitor Companies of PROK by Market Capitalization
Companies near ProKidney Corp. in the global market cap rankings as of March 19, 2026.
Key companies related to ProKidney Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ProKidney Corp. Historical Marketcap From 2021 to 2026
Between 2021 and today, ProKidney Corp.'s market cap moved from $1.40 Billion to $ 294.41 Million, with a yearly change of -28.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $294.41 Million | -7.14% |
| 2025 | $317.06 Million | +32.54% |
| 2024 | $239.21 Million | -5.06% |
| 2023 | $251.95 Million | -74.05% |
| 2022 | $971.00 Million | -30.71% |
| 2021 | $1.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of ProKidney Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $294.41 Million USD |
| MoneyControl | $294.41 Million USD |
| MarketWatch | $294.41 Million USD |
| marketcap.company | $294.41 Million USD |
| Reuters | $294.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.